Press-release for stocks related to trial

Prices are updated after-hours

tags : Trial crawled time : 06:00

save search

Valneva Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate
Published: 2024-03-26 (Crawled : 06:00) - globenewswire.com
DVAX | $11.75 -0.76% -0.77% 1.4M

Health Technology

| -5.28% | O: 0.72% H: 0.4% C: -1.75%
candidate vaccine valneva trial

Molecular Partners to Present Initial Data from Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at the 65th ASH Annual Meeting and Exposition
Published: 2023-11-02 (Crawled : 06:00) - globenewswire.com
MOLN | $3.88 -3.54% 520

Professional, Scientific, and T...

| 6.3% | O: 9.32% H: 5.26% C: 4.76%
mp0533 ongoing aml meeting trial molecular

Freeline Presents Positive New Data from Phase 1/2 GALILEO-1 Trial of FLT201, Its Novel Gene Therapy Candidate, in Gaucher Disease at ESGCT 30th Annual Congress
Published: 2023-10-25 (Crawled : 06:00) - globenewswire.com
FRLN | $6.48 0.0% 0

Health Technology

| 28.19% | O: -0.69% H: 4.18% C: 3.59%
flt201 disease congress positive trial therapy

NANOBIOTIX Announces Updated Preliminary Results From Phase 1 Pancreatic Cancer Trial and New Exploratory Analysis From Completed Phase 1 Head and Neck Cancer Trial at ESMO 2023
Published: 2023-10-23 (Crawled : 06:00) - globenewswire.com
NBTX | $5.79 1.05% 1.04% 27K

Manufacturing

| -9.05% | O: 0.0% H: 0.0% C: -0.16%
cancer pancreatic trial results

Positive Results Announced from Phase 3 OCARINA II Trial Evaluating Roche's OCREVUS® (ocrelizumab) with Halozyme's ENHANZE® Drug Delivery Technology in Patients with Multiple Sclerosis
Published: 2023-07-13 (Crawled : 06:00) - prnewswire.com
HALO M | $38.94 0.59% 0.59% 560K

Health Technology

| 4.09% | O: 0.97% H: 5.14% C: 4.42%
ocrevus drug positive sclerosis technology trial results

First Patient Dosed in SAR’514 / IPH6401 Phase 1/2 Clinical Trial in Relapsed/Refractory Multiple Myeloma
Published: 2023-07-11 (Crawled : 06:00) - biospace.com/
SNY | News | $47.69 1.15% 1.13% 1.7M

Health Technology

| -10.92% | O: -0.12% H: 0.0% C: 0.0%
iph6401 trial

Christian Mingle free trial offer â 2 measures to Saving (No marketing Code)
Published: 2023-07-06 (Crawled : 06:00) - nxtenergy.com
NSFDF | $0.1212 317.8% 12K

Industrial Services

| Email alert Add to watchlist
free trial

Novartis Kisqali® Phase III NATALEE trial meets primary endpoint at interim analysis demonstrating clinically meaningful benefit in broad population of patients with early breast cancer
Published: 2023-03-27 (Crawled : 06:00) - globenewswire.com
PFE | News A | $26.32 0.23% 0.0% 24M

Health Technology

| -34.98% | O: 0.37% H: 0.2% C: -0.79%
NVS | News | $97.28 2.27% 0.31% 3.7M

Health Technology

| 13.37% | O: 6.51% H: 1.75% C: 1.4%
kisqali breast cancer novartis trial

UroGen Announces New Data from the OLYMPUS Trial that Shows Median Durability of Response of 28.9 Months for JELMYTO®, the Only Non-Surgical, Chemoablative Treatment for Adults with Low-Grade Upper Tract Urothelial Cancer
Published: 2022-12-02 (Crawled : 06:00) - biospace.com/
URGN | $14.51 0.97% 0.96% 220K

Health Technology

| 64.6% | O: -1.49% H: 3.84% C: -2.44%
jelmyto treatment trial response cancer

Innate Pharma Presents Data From Ongoing Phase 2 TELLOMAK Trial Demonstrating Clinical Activity of Lacutamab in Advanced Mycosis Fungoides
Published: 2022-09-23 (Crawled : 06:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K

Health Technology

| 21.97% | O: 5.45% H: 0.0% C: -8.46%
NVO | News | $128.64 2.7% -0.07% 3.7M

Health Technology

| 27.41% | O: -0.53% H: 0.81% C: 0.14%
SNY | News | $47.69 1.15% 1.13% 1.7M

Health Technology

| 18.53% | O: -1.69% H: 0.0% C: 0.0%
IPHA | $2.425 -7.02% 2.7K

Health Technology

| -2.02% | O: -2.02% H: 0.41% C: -3.72%
ongoing pharma trial phase 2

Sandoz announces further progress on its biosimilar pipeline, with release of positive results for denosumab integrated Phase I/III clinical trial
Published: 2022-09-19 (Crawled : 06:00) - globenewswire.com
NVS | News | $97.28 2.27% 0.31% 3.7M

Health Technology

| 17.51% | O: -0.52% H: 0.69% C: 0.62%
AMGN | News | $273.69 0.66% 0.65% 2.5M

Health Technology

| 17.64% | O: -0.22% H: 0.1% C: 0.05%
biosimilar trial positive

Celyad Oncology Announces FDA Lifts Clinical Hold of CYAD-101-002 Phase 1b Trial
Published: 2022-08-01 (Crawled : 06:00) - globenewswire.com
CYAD | $0.47 -12.49% 49K

Health Technology

| -72.51% | O: 46.2% H: 13.2% C: -2.0%
cyad-101 fda trial phase 2b clinical hold

Dupixent® (dupilumab) Phase 3 Trial Shows Positive Results in Children 1 to 11 Years of Age with Eosinophilic Esophagitis
Published: 2022-07-14 (Crawled : 06:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K

Health Technology

| -6.51% | O: -1.46% H: 0.09% C: 0.09%
SNY | News | $47.69 1.15% 1.13% 1.7M

Health Technology

| -6.55% | O: -1.27% H: 0.0% C: 0.0%
REGN | News | $906.84 0.74% 0.74% 340K

Health Technology

| 49.52% | O: -1.0% H: 1.64% C: 0.48%
dupixent children trial positive results phase 3

Press Release: Update on Cialis® Rx-to-OTC Switch Actual Use Trial
Published: 2022-05-30 (Crawled : 06:00) - globenewswire.com
SNYNF | News | $92.7 -2.18% 600K

Health Technology

| Email alert Add to watchlist
SNY | News | $47.69 1.15% 1.13% 1.7M

Health Technology

| Email alert Add to watchlist
cialis trial